Healthcare Industry News: Bristol-Myers Squibb
News Release - September 3, 2014
Intensity Therapeutics, Inc. Appoints Ian B. Walters M.D., MBA as Vice President and Chief Medical OfficerWESTPORT, Conn.--(Healthcare Sales & Marketing Network)--Intensity Therapeutics, Inc., a privately-held specialty pharmaceutical company developing novel products to treat solid tumor cancers, announced today that Ian B. Walters M.D., MBA, has been appointed as Vice President, Clinical Development & Chief Medical Officer. Dr. Walters, who will initially work part-time, will oversee the company's clinical strategy and activities, including direct supervision of clinical research, clinical operations, medical affairs and drug safety and surveillance.
"I am exceptionally pleased that Ian is joining the Intensity team," said Lewis H. Bender, President and CEO of Intensity Therapeutics. "Throughout his career, Ian has consistently demonstrated both leadership and expertise in drug development, including the advancement of multiple cancer compounds from research stages through approval. He has an impressive track record with extensive experience in clinical and regulatory processes, both domestically and internationally. Following our recently completed type B, pre-IND meeting with the U.S. Food and Drug Administration’s (FDA) Division of Oncology Products, we have a development plan that we anticipate will lead to initial human testing of our first cancer drug product, INT230-6, in the second half of 2015.”
Dr. Walters remarked, “I am excited to help Intensity Therapeutics develop and execute its first clinical trial. I believe in situ chemovaccination is a novel platform that leverages the patient’s own tumor antigens to activate a specific and durable anti-tumor immune response. This technology should enable highly personalized therapy without complicated ex-vivo processing.”
Dr. Walters brings over 15 years of oncology/immunology drug development experience to Intensity Therapeutics. Dr. Walters has been a consultant to biotech, pharma and investment companies specializing in the evaluation, prioritization, and development of innovative technologies in the treatment of severe diseases. He has worked in multiple biotech companies on corporate development, translational medicine, clinical development and medical affairs. Dr. Walters spent seven years at Bristol-Myers Squibb (BMS), where he led clinical research and matrix development teams. During his tenure there he contributed to the development of multiple immuno-oncology products (Yervoy® and Nivolimumab (anti-PD-1)), as well as the licensing and partnering strategy for other immuno-oncologic agents. Before entering the private sector, Dr. Walters was a lead investigator at the Rockefeller University and initiated cutting edge immunology research to understand the mechanism of action of several compounds.
Dr. Walters received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of The University of Pennsylvania.
About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a specialty pharmaceutical company whose mission is to greatly extend the lives of patients with solid tumor cancers. Intensity Therapeutics is pioneering a new approach to treat cancer referred to as in situ chemovaccination. The Company creates novel, proprietary formulations of proven chemotherapy drugs. These products, when injected directly into tumors result in significantly greater tumor growth inhibition and increased survival compared to conventionally delivered chemotherapy. The technology attenuates (kills) a tumor in a manner that allows for the adaptive immune system to recognize the cancer to attack untreated tumors and prevent disease recurrence. Further information can be found at www.intensitytherapeutics.com.
This press release contains forward-looking statements regarding Intensity Therapeutics’ plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.
Source: Intensity Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.